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Abstract. A patient with chronic liver disease was treated with large doses of meben
dazole for a hepatic hydatid cyst. Eighteen days after beginning treatment he developed
marrow aplasia which reverted to normal after the drug was stopped. This is the sixth
patient described as developing marrow aplasia when treated with large doses of meben
dazole. We suggest that the aplasia is related to the dose ofthe drug, and that the patient's
chronic liver disease was an important factor in its genesis. Patients treated with large doses
of mebendazole should have their blood counts monitored during treatment.
Mebendazole is a broad spectrum anthel
mintic drug which, in low doses, has been used
a great deal with few adverse effects.' 2 In large
doses it is useful in the treatment of human hy
4 but marrow aplasia may occur dur
ing treatment.@7 We describe a case of marrow
aplasia due to mebendazole in a patient with
chronic liver disease.
CASE STUDY
A male aged 65 years had undergone splenec
tomy at the age of 62 for idiopathic thrombo
cytopenic purpura. At 64 years a diagnosis of
chronic liver disease was made. When admitted
to our department because of pain in the right
hypochondrium he had jaundice, hepatomegaly
and a right pleural effusion. The effusion was an
exudate rich in eosinophils. Analyses showed pe
ripheral eosinophilia (1.24 x 10@/l),hematocrit
37%, hemoglobin 13 g/dl, leukocytes 11.4 x 10@/
1,platelets 149 x l0@/l, prothrombin time 50%,
alanine aminotransferase 104 U/l, aspartate ami
notransferase 106 U/l, alkaline phosphatase 180
U/I, bilirubin 89 Mmol/l, albumin 27 g/l, globulin
51 g/l, HBsAg and anti-HBs negative. An ab
dominal computerized tomograph revealed a
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mass in the right lobe of the liver suggestive of
a hydatid cyst. Serology for Echinococcus was
positive (indirect hemagglutination â€˜/25w,latex
agglutination â€˜/@).Surgical resection was impos
sible because ofhis poor general health. Meben
dazole therapy was started at a dose ofl,500 mg/
day. Eighteen days later he presented with ab
dominal distension, fever, chills and right sub
mandibular pain. Examination revealed erythe
ma with congestion of the posterior fold of the
soft palate and mucocutaneous pallor. The he
matocrit was 24%, hemoglobin 7.8 g/dl, leuko
cytes 2.7 x l0@/l (eosinophils 28%, neutrophils
28%, lymphocytes 44%), and platelets 180 x
lO@/l. The hematocrit and leukocyte counts fell
further over the next 5 days. Marrow aspirate
and biopsy showed hypocellular bone marrow,
with severe diminution in both white and cryth
rocyte series and slight diminution in the mega
karyocyte series. There was moderate lympho
cyte and plasma cell infiltration of reactive
character, depletion of iron deposits and toxic
changes in the stroma manifested by hemorrhage
and edema. Staphylococcz&r aureu@ was isolated
in 2 blood cultures. The patient's progress was
good after antibiotic therapy, transfusion of4 U
ofblood and suspension of mebendazole thera
py; after 17 days the leukocyte count was 8.3 x
lO@/1(eosinophils 5%, band forms 2%, neutro
phils 54%, lymphocytes 28%, monocytes 11%).
DISCUSSION
This patient is the sixth described in the En
gush language literature who developed neutro
350
DaysHe
Doseofmato
Authormg/ kg/dtreatmentcrit %WBC
x
lO'/IPlatelets
x
lO'/lBone marrowLiverdiseaseEvolutionMiskovitz
et al.55019272.2210HypocellularNoneRecuperation
in 14daysWilson
et al.65014270.388Aplasia of erythroid
and myeloid seriesAlcoholichepatitisSepsis;
deathHarris*5018â€”â€”â€”Not
reportedâ€”RecuperationLevin
etal.71st
case5019â€”1.5Adequate on
smearNot
doneNoneRecuperation
in 12days2nd
case4026220.232HypocellularNoneBacteremia; re
cuperation in
16daysPresent
case3023191.7180HypocellularChronic
liver
diseaseBacteremia;
re
cuperation in
17daysS
Personal communication.cited byWilson et al.'
351MARROW APLASIA DUE TO MEBENDAZOLE
TABLE 1
Reported cases ofneutropenia due to mebendazole in English language literature
penia after treatment with large doses of meben
dazole. The data which suggest the drug as the
cause ofmarrow aplasia in our patient are: 1) the
appearance of anemia and leukopenia 18 days
after the start oftreatment; 2) signs ofbone mar
row toxicity manifested by hemorrhage and ede
ma in the stroma; 3) remission 17 days after
stopping treatment; and 4) the absence of other
etiological factors.
Our patient presented characteristics which
were similar to those of the 5 cases previously
described,@7 with the same changes in the mar
row biopsy and the same latency period (Table
1). We draw attention to the fact that this is
the second patient with liver disease who has
developed aplasia. We postulate that aplasia is
dose-related since: 1) there have been no re
ported instances of aplasia in any of the thou
sands ofpatients with intestinal parasitosis treat
ed with low doses of mebendazole (the most
widely used schedule is 100â€”300mg twice daily
for 3 days); 2) it has appeared only in patients
treated with large doses; and 3) it has been re
versed in almost all of them. In the only case in
which plasma levels of mebendazole were mea
sured they were very high,7 giving further support
to the hypothesis of dose-related toxicity. The
chronic liver disease in our patient, with possible
alteration in the metabolism ofmebendazole and
thus a possible increase in its plasma levels, could
be an important factor in the genesis ofthe apla
sia.
In conclusion, we recommend frequent mon
itoring ofblood counts during high dose meben
dazole treatment, especially in patients with liver
disease.
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